Skip to main content

Stem Cell Treatment May Calm MS Brain Inflammation

By MS Buddy ·

Summarized from Neurology(R) neuroimmunology & neuroinflammation, Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Research by Laura Cooney, Paolo Muraro and 14 colleagues at Imperial College London, Hospital Universitario Ramón y Cajal and 3 other institutions in the United States, the United Kingdom and Spain.

Key Takeaway

In 24 people with severe MS, a stem cell transplant was followed by years of lower signs of inflammation and nerve damage.

Credibility
Interest
Share:2 min read

What They Found

Researchers followed 24 people with severe MS after a transplant that uses their own stem cells to rebuild the immune system. For several years, blood and spinal fluid tests showed lower levels of many substances linked to inflammation. A marker of nerve damage also fell, which fits with the disease becoming less active. Two substances in spinal fluid rose instead, and researchers do not yet know what those changes mean. Blood and spinal fluid often told different stories, much like checking the weather outside does not always tell you what it feels like inside a house.

Who Should Care and Why

People with severe MS and their caregivers may find this study useful when discussing treatment options with an MS specialist. It offers clues about what happens inside the body after this transplant, rather than showing only whether symptoms or scans change. Healthcare providers may need both blood and spinal fluid tests to understand those changes more fully. A spinal fluid test requires a needle in the lower back, so its possible value must be weighed against the burden of the test. These findings do not call for a change to your daily care routine, but they can help you ask what a test result can and cannot tell you.

Important Considerations

The study included only 24 people with severe MS, so its results may not apply to everyone with MS. It tracked changes after treatment but cannot prove that lower test markers will lead to better symptoms for any one person. Some markers rose, and the meaning of those changes needs more study.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Neurology(R) neuroimmunology & neuroinflammation by et al.. Reproduced from the PubMed record.

Autologous hematopoietic stem cell transplantation (AHSCT) can induce long-lasting immune tolerance and disease quiescence in patients with severe multiple sclerosis (MS), but the underlying mechanisms are not well understood. We hypothesized that AHSCT would induce persistent decreases in inflammatory cytokines, chemokines, and axoglial damage biomarkers in serum and CSF. Longitudinal serum and CSF samples were obtained from 24 participants with severe MS undergoing AHSCT in the HALT-MS trial (NCT00288626), with serum collected at 9 time points from pretreatment through month 60 and CSF collected at 3 time points, including pretreatment, month 24, and month 48. Approximately 50 soluble biomarkers were analyzed to determine treatment-induced changes and associations with disease activity, including clinical and MRI parameters. AHSCT resulted in decreased expression of many proinflammatory cytokines, chemokines, and neuroinflammatory markers for several years in both serum and CSF, including neurofilament light chain (NfL). CSF levels of glial fibrillary acid protein and IL-7, on the contrary, increased after treatment. Expansion of cytomegalovirus and/or Epstein-Barr virus early after AHSCT resulted in transient increases in inflammatory cytokines in serum, but these changes did not persist. Changes in serum were largely distinct from changes in CSF, and concentrations of cytokines and chemokines in serum rarely correlated with concentrations in CSF, except for NfL. These results confirm the hypothesis that AHSCT results in long-lasting reductions in inflammatory cytokines, chemokines, and axoglial damage markers, consistent with persistent disease quiescence. The lack of relationships between biomarkers in serum and CSF suggests that these samples largely reflect distinct immunologic processes and compartments, and that analysis of CSF may be warranted for deeper understanding of disease processes in the CNS despite the challenges associated with performing lumbar punctures. Expression of IL-7 in CSF may be an underappreciated biomarker of the inflammatory state in the CNS and warrants further study.

Explore more research

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two views of spinal cord nerve endings, with fewer chemical particles around the endings on the right.
Lab drug cut chemical release in MS-like mouse tissue

11/15/2026

In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More
A winding path links a DNA strand and a partly broken ring in a simple two-color print.
Review explores how immune genes may shape MS damage

11/13/2026

A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting

Read More
Two differently colored molecular shapes near immune cells and a myelinated nerve fiber on a pale background.
Review links vitamin D and vitamin A immune signals to MS

11/13/2026

This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea

Read More
A folded paper shape beside two winding paths with slightly smoother stretches, in muted colors.
In MS-like mice, treatment helped movement and thinking

11/12/2026

In mice with an MS-like disease, a lab-made protein improved movement and thinking. Researchers also

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.